BMY Stock Recent News
BMY LATEST HEADLINES
Zenas BioPharma, which is developing immunology-based therapies, said on Friday it is targeting a valuation of as much as $689.7 million in its initial public offering in the United States.
Bristol-Myers Squibb Company (NYSE:BMY ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 1:05 PM ET Company Participants Chris Boerner - Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Okay, great. Thanks for joining us everybody.
Recent results from Bristol Myers Squibb support an improving outlook. The company is benefiting from strong demand for its new medications.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients.
Bristol Myers Squibb (BMY) closed at $49.95 in the latest trading session, marking a +0.46% move from the prior day.
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
Wednesday, Neurocrine Biosciences, Inc. NBIX topline data for its Phase 2 clinical study of NBI-1117568 (NBI-‘568) in adults with schizophrenia.
The benchmark S&P 500 index is way up over the past year, but some of its dividend-paying components haven't participated in the gains. Bristol Myers Squibb's dividend offers a high yield that could rise on the back of several new drugs with soaring sales.
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.